Showing results (71-80 of 199) with videos related to
Sort By:
Pageof 20
Rheumatic Diseases Clinics of North America|December 1, 1987
T cell regulatory disturbances in the rheumatic diseasesS D Alpert, J Koide, S Takada, et al.European Journal of Immunology|July 1, 1993
Activation with superantigens induces programmed death in antigen-primed CD4+ class II+ major histocompatibility complex T lymphocytes via a CD11a/CD18-dependent mechanismN K Damle, G Leytze, K Klussman, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1993
Proliferation of human T lymphocytes induced with superantigens is not dependent on costimulation by the CD28 counter-receptor B7N K Damle, K Klussman, G Leytze, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1992
Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytesN K Damle, K Klussman, P S Linsley, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1989
Evidence for involvement of the gamma, delta T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clonesA Rivas, J Koide, M L Cleary, et al.Arthritis and Rheumatism|September 1, 1994
An open study of dehydroepiandrosterone in systemic lupus erythematosusR F van Vollenhoven, E G Engleman, J L McGuireTransplantation|June 1, 1989
Evidence that cytotoxic lymphocytes alter and traverse allogeneic endothelial cell monolayersJ R Bender, R Pardi, J Kosek, et al.European Journal of Immunology|June 1, 1997
Differential response of CD4+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigenL R Soares, A Rivas, C Ruegg, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1998
V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocationL R Soares, L Tsavaler, A Rivas, et al.Arthritis and Rheumatism|December 1, 1995
Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trialR F van Vollenhoven, E G Engleman, J L McGuirePageof 20